Literature DB >> 20818438

Remodeling of VE-cadherin junctions by the human herpes virus 8 G-protein coupled receptor.

J Dwyer1, A Le Guelte, E M Galan Moya, M Sumbal, A Carlotti, L Douguet, J S Gutkind, P A Grange, N Dupin, J Gavard.   

Abstract

Kaposi Sarcoma (KS) are opportunistic tumors, associated with human herpes virus 8 (HHV8) infection. KS development is highly favored by immune-depression and remains the second most frequent tumor in acquired immune deficiency syndrome patients. Although it has been shown that experimental expression of the HHV8 G-protein-coupled receptor (vGPCR) in the endothelial compartment is alone sufficient to recapitulate the formation and progression of KS-like lesions, its functional effects on endothelial homeostasis are not fully understood. Here we show that vGPCR expression in endothelial cells induces an increase in paracellular permeability both in vivo and in vitro. By using pharmacological inhibitors and small interference RNA-based knockdown, we demonstrate an essential role for the PI(3)Kinase-γ/Rac nexus in vGPCR-mediated permeability. This was further accompanied by dramatic remodeling of VE-cadherin-dependent cell-cell junctions. Importantly, this in vitro vGPCR-initiated signaling signature was observed in a large panel of human KS. Altogether, our results support the hypothesis that endothelial vGPCR signaling is co-opted in KS, and unveil new key cellular targets for therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20818438     DOI: 10.1038/onc.2010.411

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  14 in total

1.  Latent KSHV infection increases the vascular permeability of human endothelial cells.

Authors:  Christophe Guilluy; Zhigang Zhang; Prasanna M Bhende; Lisa Sharek; Ling Wang; Keith Burridge; Blossom Damania
Journal:  Blood       Date:  2011-08-31       Impact factor: 22.113

Review 2.  Novel approaches to inhibitor design for the p110β phosphoinositide 3-kinase.

Authors:  Hashem A Dbouk; Jonathan M Backer
Journal:  Trends Pharmacol Sci       Date:  2013-02-12       Impact factor: 14.819

Review 3.  Endothelial permeability and VE-cadherin: a wacky comradeship.

Authors:  Julie Gavard
Journal:  Cell Adh Migr       Date:  2013-12-05       Impact factor: 3.405

4.  Recombinant tissue-type plasminogen activator transiently enhances blood-brain barrier permeability during cerebral ischemia through vascular endothelial growth factor-mediated endothelial endocytosis in mice.

Authors:  Yasuhiro Suzuki; Nobuo Nagai; Kasumi Yamakawa; Yoshinori Muranaka; Kazuya Hokamura; Kazuo Umemura
Journal:  J Cereb Blood Flow Metab       Date:  2015-07-29       Impact factor: 6.200

Review 5.  Human tumour viruses and the deregulation of cell polarity in cancer.

Authors:  Lawrence Banks; David Pim; Miranda Thomas
Journal:  Nat Rev Cancer       Date:  2012-12       Impact factor: 60.716

6.  Glioblastoma cell-secreted interleukin-8 induces brain endothelial cell permeability via CXCR2.

Authors:  Julie Dwyer; Jagoda K Hebda; Armelle Le Guelte; Eva-Maria Galan-Moya; Sherri S Smith; Sandy Azzi; Nicolas Bidere; Julie Gavard
Journal:  PLoS One       Date:  2012-09-20       Impact factor: 3.240

7.  Latent KSHV infection of endothelial cells induces integrin beta3 to activate angiogenic phenotypes.

Authors:  Terri A DiMaio; Kimberley D Gutierrez; Michael Lagunoff
Journal:  PLoS Pathog       Date:  2011-12-08       Impact factor: 6.823

8.  KSHV Induction of Angiogenic and Lymphangiogenic Phenotypes.

Authors:  Terri A Dimaio; Michael Lagunoff
Journal:  Front Microbiol       Date:  2012-03-30       Impact factor: 5.640

Review 9.  Endothelial permeability and VE-cadherin: a wacky comradeship.

Authors:  Julie Gavard
Journal:  Cell Adh Migr       Date:  2014       Impact factor: 3.405

10.  Endotoxin-induced monocytic microparticles have contrasting effects on endothelial inflammatory responses.

Authors:  Beryl Wen; Valery Combes; Amandine Bonhoure; Babette B Weksler; Pierre-Olivier Couraud; Georges E R Grau
Journal:  PLoS One       Date:  2014-03-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.